A site called The Science of Parkinson’s (Plain English information about the research being conducted on Parkinson’s) recently published a substantive post examining results from the Parkinson’s / Nicotinamide Riboside “NR” (FAQs) (Reviews) clinical trial out of Norway published in March. While we encourage you to read the post in its entirety, here’s the concluding key quote:

From “The Science of Parkinson’s“:

“Mitochondria are the energy producing power stations of cells. The biomolecule NAD is a key component of that energy production process, and recently researchers have been testing if oral treatment with a particular component of NAD production pathway can help to enhance mitochondrial function. They have found that Nicotinamide Riboside “NR” (FAQs) (Reviews) can increase energy levels in the brains of people with Parkinson’s in a small pilot study and they are now testing this agent in a longer term study to determine if it can impact the progression of the condition.

Mitochondrial dysfunction has long been associated with Parkinson’s, and we have been waiting to see if therapies that boost the function of this tiny cellular structures can help to slow down the progression of PD. A struggling mitochondria can cause a lot of cellular stress, which may make cells more vulnerable to additional stressors. Thus, improving the health of mitochondria represents a very compelling experimental therapeutic approach (see the mitochondria section of the 2022 Road Ahead post for additional agents targeting mitochondria).

An additional compelling feature of Nicotinamide Riboside “NR” (FAQs) (Reviews) is that if this treatment is found to be safe and well tolerated over a long period of time (such as 1 year in the ongoing NOPARK study discussed above), it will hopefully be a straightforward process to involving it in combinations with other agents that target additional aspect of Parkinson’s-associated biology (such as GCase activation or LRRK2 inhibition). For a long time readers have been asking when will the Parkinson’s field follow other areas of medical research and start investigating combination therapies. With progress in areas like Nicotinamide Riboside “NR” (FAQs) (Reviews), GLP-1R agonists and other experimental approaches, we may soon be on the edge of combination approaches for Parkinson’s”

Read the full post HERE.

Related:

  • New Phase 1 Clinical Trial Results Show B3 Vitamin Nicotinamide Riboside (NR) as a Potential Neuroprotective Therapy for Parkinson`s Disease. Why is This Important? (Link)
  • What’s the Latest on the Parkinson’s Study Using B3 Vitamin Supplement Nicotinamide Riboside (NR)? (Link)
  • Should Those Suffering from Parkinson’s Disease Supplement with Nicotinamide Riboside (NR)? (Link)
  • “NR” and Alzheimer’s (FAQs)
  • “NR” (FAQs) (Consumer Reviews)

FOLLOW us on Twitter @RaisingNAD